| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 169 |
| 1 | INFLIXIMAB | 168 |
| 2 | METHOTREXATE SODIUM | 168 |
| 3 | ETANERCEPT | 167 |
| 4 | SULFASALAZINE | 166 |
| 5 | METHOTREXATE | 164 |
| 6 | LEFLUNOMIDE | 163 |
| 7 | TOCILIZUMAB | 161 |
| 8 | ABATACEPT | 160 |
| 9 | RITUXIMAB | 150 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DIMENHYDRINATE | 97 | 0.0149 |
| 1 | FEBUXOSTAT | 109 | 0.0107 |
| 2 | GOLD | 24 | 0.0064 |
| 3 | COLCHICINE | 107 | 0.0054 |
| 4 | IBUPROFEN AND DIPHENHYDRAMINE CITRATE | 75 | 0.0036 |
| 5 | SULFASALAZINE | 166 | 0.0030 |
| 6 | RISEDRONATE SODIUM | 64 | 0.0028 |
| 7 | DEXLANSOPRAZOLE | 97 | 0.0028 |
| 8 | TETRACAINE HYDROCHLORIDE | 1 | 0.0025 |
| 9 | TOCILIZUMAB | 161 | 0.0022 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 172 |
| 1 | Aminosalicylate [EPC] | 166 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 164 |
| 3 | Antirheumatic Agent [EPC] | 163 |
| 4 | Interleukin-6 Receptor Antagonist [EPC] | 161 |
| 5 | Selective T Cell Costimulation Modulator [EPC] | 160 |
| 6 | CD20-directed Cytolytic Antibody [EPC] | 150 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 122 |
| 8 | Corticosteroid [EPC] | 112 |
| 9 | Interleukin-12 Antagonist [EPC] | 109 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Alkaloid [EPC] | 107 | 0.0054 |
| 1 | Standardized Chemical Allergen [EPC] | 24 | 0.0021 |
| 2 | Antirheumatic Agent [EPC] | 163 | 0.0021 |
| 3 | Interleukin-6 Receptor Antagonist [EPC] | 161 | 0.0020 |
| 4 | Aminosalicylate [EPC] | 166 | 0.0019 |
| 5 | Selective T Cell Costimulation Modulator [EPC] | 160 | 0.0017 |
| 6 | Interleukin-12 Antagonist [EPC] | 109 | 0.0017 |
| 7 | Interleukin-23 Antagonist [EPC] | 109 | 0.0015 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 150 | 0.0009 |
| 9 | Xanthine Oxidase Inhibitor [EPC] | 109 | 0.0009 |